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Abstract
To	overcome	the	problem	of	overlooking	colorectal	tumors,	a	new	and	highly	sensi-
tive	modality	of	colonoscopy	is	needed.	Moreover,	it	is	also	important	to	establish	a	
new	modality	to	evaluate	viable	tumor	volume	in	primary	lesions	of	colorectal	cancer	
(CRC)	during	 chemotherapy.	Therefore,	we	carried	out	molecular	 imaging	of	 colo-
rectal	tumors	targeting	epidermal	growth	factor	receptor	(EGFR),	which	is	highly	ex-
pressed	on	tumor	cells,	for	evaluating	chemotherapeutic	efficacy	and	for	endoscopic	
detection	of	colorectal	adenomas.	We	first	attempted	to	 image	five	CRC	cell	 lines	
with	various	levels	of	EGFR	expression	using	an	Alexa	Fluor-labeled	anti-EGFR	mon-
oclonal	 antibody	 (AF-EGFR-Ab).	A	 strong	 fluorescence	 signal	was	observed	 in	 the	
cells	depending	on	the	level	of	EGFR	expression.	When	nude	mice	xenografted	with	
LIM1215	CRC	cells,	which	highly	express	EGFR,	were	i.v.	injected	with	AF-EGFR-Ab,	
a	strong	fluorescence	signal	appeared	in	the	tumor	with	a	high	signal	to	noise	ratio,	
peaking	at	48	hours	after	injection	and	then	gradually	decreasing,	as	shown	using	an	
IVIS	Spectrum	system.	When	the	xenografted	mice	were	treated	with	5-fluoroura-
cil,	fluorescence	intensity	in	the	tumor	decreased	in	proportion	to	the	viable	tumor	
cell	volume.	Moreover,	when	the	colorectum	of	azoxymethane-treated	rats	was	ob-
served	using	a	thin	fluorescent	endoscope	with	AF-EGFR-Ab,	all	10	small	colorectal	
adenomas	(≤3	mm)	were	detected	with	a	clear	fluorescence	signal.	These	preliminary	
results	of	animal	experiments	suggest	that	EGFR-targeted	fluorescent	molecular	im-
aging	may	be	useful	for	quantitatively	evaluating	cell	viability	in	CRC	during	chemo-
therapy,	and	also	for	detecting	small	adenomas	using	a	fluorescent	endoscope.
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1  | INTRODUC TION
Colorectal	 cancer	 is	 one	 of	 the	 leading	 causes	 of	 cancer-related	
death	worldwide.1	 It	 is	well	known	that	CRC	develops	mainly	from	
colorectal	 adenoma,	 a	 precancerous	 lesion	 in	 the	 colorectum.2-4 
Therefore,	 it	 is	 important	 to	 remove	colorectal	 adenoma	before	 it	
develops	into	cancer.	However,	it	has	been	reported	that	15%-32%	
of	colorectal	tumors	are	overlooked	during	colonoscopy.5	Thus,	im-
proved	endoscopy	capable	of	more	sensitive	detection	of	colorectal	
tumors	is	needed.
In	addition,	evaluation	of	tumor	size	in	response	to	chemotherapy	
is	critical	in	the	treatment	of	metastatic	CRC.6	Currently,	response	to	
treatment	 in	CRC	 is	 evaluated	 by	CT	 using	RECIST	 criteria.7 Only 
measurable	metastatic	 lesions	 in	 patients	with	CRC	 are	 evaluated	
by	 measuring	 tumor	 size	 in	 CT	 images	 based	 on	 RECIST	 criteria.	
However,	it	is	difficult	to	evaluate	viable	tumor	cells	accurately	be-
cause	the	central	part	of	 the	tumor	often	undergoes	necrosis	as	a	
result	of	chemotherapy	or	other	 factors.8-10	Moreover,	 there	 is	no	
method	to	objectively	evaluate	tumor	volume	of	primary	lesions	in	
the	 colorectum	 during	 chemotherapy.	 A	 new	 imaging	modality	 to	
accurately	assess	viable	tumor	volume	of	CRC	is	therefore	needed.
Molecular	 imaging	 is	 a	good	candidate	modality	 for	 the	detec-
tion	of	small	colorectal	tumors	with	high	sensitivity	and	accurately	
evaluates	the	viability	of	colorectal	tumors.	Furthermore,	molecular	
imaging	also	makes	 it	possible	to	distinguish	malignant	and	benign	
lesions,	and	to	accurately	assess	tumor	margin.11	However,	a	prac-
tical	molecular	 imaging	 technology	 that	 improves	 the	detection	of	
small	tumors	and	enables	evaluation	of	viable	tumor	cell	volume	be-
fore	and	after	chemotherapy	has	yet	to	be	established.12
Epidermal	growth	factor	receptor	 is	a	 transmembrane-type	ty-
rosine	kinase.	EGFR	 is	 commonly	expressed	on	 the	cell	 surface	of	
CRC	 and	precancerous	 adenomas,	 and	 is	 strongly	 associated	with	
proliferation,	 invasion,	metastasis,	poor	prognosis,	and	early	recur-
rence	of	CRC.13-16	EGFR	is	expressed	on	the	cell	membrane	surface,	
and	the	expression	level	is	highest	in	cancer,	moderate	in	adenoma,	
and	very	low	in	normal	epithelia.	Thus,	EGFR	is	suitable	as	a	target	
for	molecular	imaging	of	colorectal	tumors.
Although	 several	 studies	 on	molecular	 imaging	 of	 CRC	 target-
ing	EGFR	have	been	published,	17-21	no	studies	on	molecular	imaging	
for	precancerous	adenomas	targeting	EGFR	have	been	reported.	In	
addition,	no	studies	have	 investigated	the	utility	of	EGFR-targeted	
molecular	imaging	of	viable	tumor	cells	in	CRC	before	and	after	treat-
ment	with	anticancer	agents.	In	the	present	study,	we	first	examined	
whether	fluorescence-labeled	anti-EGFR	antibody	is	able	to	visual-
ize	CRC	in	vitro	and	in	vivo	depending	on	EGFR	expression	level.	We	
also	investigated	the	utility	of	EGFR-targeted	molecular	imaging	for	
the	evaluation	of	viable	cell	volume	before	and	after	chemotherapy	
in	animal	models	of	CRC.	We	then	carried	out	molecular	imaging	of	
small	 colorectal	 adenomas	 in	 a	 rat	model	 using	 a	 fluorescence-la-
beled	anti-EGFR	antibody.
2  | MATERIAL S AND METHODS
2.1 | Cell lines
The	 CRC	 cell	 lines	 DLD-1,	 COLO320DM,	 HT-29,	 LIM1215,	 and	
M7609	were	used.	DLD-1	and	COLO320DM	cell	lines	were	obtained	
from	Health	Science	Research	Resources	Bank.	HT-29	and	LIM1215	
cell	lines	were	purchased	from	ATCC	and	European	Collection	of	Cell	
Cultures,	respectively.	The	M7609	cell	 line	was	kindly	provided	by	
Dr	R.	Machida	(Hirosaki	University).	COLO320DM	cells	were	main-
tained	 in	DMEM	supplemented	with	10%	FBS,	50	U/mL	penicillin,	
and	50	U/mL	streptomycin.	HT-29	cells	were	maintained	in	McCoy's	
5a	medium	supplemented	with	10%	FBS.	The	other	cell	 lines	were	
cultured	in	RPMI-1640	medium	supplemented	with	10%	FBS,	50	U/
mL	penicillin,	and	50	U/mL	streptomycin.	All	cells	were	cultured	at	
37°C	with	5%	CO2.
2.2 | Quantification of cell surface EGFR by 
flow cytometry
Quantitative	 flow	 cytometric	 analysis	 of	 EGFR	 on	 the	 cell	 sur-
face	 was	 carried	 out	 using	 mouse	 antihuman	 EGFR	 monoclonal	
antibody	 (sc-120;	 Santa	 Cruz	 Biotechnology,	 Dallas,	 TX,	 USA)	
and	Dako	QIFIKIT	 (Dako,	 Glostrup,	 Denmark),	 as	 described	 pre-
viously.22	 In	 brief,	 cells	were	 incubated	with	 a	mouse	 antihuman	
EGFR	 monoclonal	 antibody.	 After	 washing	 the	 cells	 with	 PBS,	
they	 were	 incubated	 with	 an	 FITC-conjugated	 F(ab′)2	 fragment	
of	goat	antimouse	IgG	polyclonal	antibody	 in	the	dark.	Then,	the	
fluorescence	intensity	of	the	cells	was	determined	by	flow	cytom-
etry	(Becton	Dickinson,	Franklin	Lakes,	NJ,	USA).	Standard	beads	
in	Dako	QIFIKIT	coated	with	a	known	amount	of	mouse	IgG	mol-
ecules	were	incubated	with	the	FITC-conjugated	F(ab′)2	fragment	
of	 goat	 antimouse	 IgG	 polyclonal	 antibody.	Number	 of	 antibody	
binding	sites	per	cell	was	calculated	by	comparing	mean	 fluores-
cence	intensity	value	of	the	cells	with	a	calibration	curve	obtained	
by	regression	analysis	of	the	mean	fluorescence	intensity	values	of	
the	standard	beads.
2.3 | In vitro cell imaging and fluorescence intensity
For	in	vitro	cell	imaging,	1	×	105	CRC	cells	were	cultured	in	35-mm	
dishes,	 and	 then	 fixed	 with	 4%	 paraformaldehyde	 and	 blocked	
with	 10%	 goat	 serum.	 The	 cells	 were	 incubated	with	 Alexa	 Fluor	
K E Y W O R D S
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488-labeled	mouse	antihuman	EGFR	monoclonal	antibody	(AF488-
EGFR-Ab;	 sc-120,	 Santa	 Cruz	 Biotechnology)	 at	 4°C	 overnight.	
Alexa	 Fluor	 488-labeled	 normal	 mouse	 IgG2a	 (sc-3891;	 Santa	
Cruz	Biotechnology)	was	used	as	a	negative	control.	After	washing	
with	PBS,	the	samples	were	mounted	with	ProLong	Gold	Antifade	
Reagent	with	DAPI	(Thermo	Fisher	Scientific,	Waltham,	MA,	USA).	
The	 cells	were	 observed	 by	 confocal	 laser	microscopy	 (Nikon	A1;	
Nikon,	 Tokyo,	 Japan)	 and	 bench	 top	 fluorescence	 microscopy	
(BIOREVO	BZ9000;	Keyence,	Osaka,	Japan).	Images	were	captured	
using	the	Nikon	A1,	and	signal	intensity	was	calculated	using	the	in-
trinsic	software	equipped	with	BIOREVO	in	each	cell.
2.4 | In vivo molecular imaging of xenograft tumors 
in mice
LIM1215	or	COLO320DM	cells	(1	×	107)	were	inoculated	into	the	
flank	of	 five	6-week-old	 female	BALB/c	nu/nu	mice	 (CLEA	Japan	
Inc.	Tokyo,	Japan),	respectively.	When	the	tumor	reached	10	mm	
in	diameter,	50	μg	Alexa	Fluor	647-labeled	mouse	antihuman	EGFR	
monoclonal	antibody	(AF647-EGFR-Ab,	sc-120	AF647;	Santa	Cruz	
Biotechnology)	was	 injected	 into	 the	 tail	 vein	 of	 the	mice	 under	
anesthesia.	 Alexa	 Fluor	 647-labeled	 normal	 IgG2a	 (sc-24637	
AF647;	Santa	Cruz	Biotechnology)	was	used	as	a	negative	control.	
Subsequently,	 fluorescent	 images	 of	 the	 xenograft	 tumor	 were	
observed	 using	 an	 IVIS	 Spectrum	 (Perkin	 Elmer,	 Waltham,	 MA,	
USA)	with	 a	640-nm	excitation	 filter	 and	 a	680-nm	emission	 fil-
ter,	 and	 recorded	 before	 injection	 (0	minute),	 and	 at	 24,	 48,	 72,	
and	 96	 hours	 after	 injection.	 To	 quantify	 fluorescence	 intensity,	
regions	of	 interest	 (ROI)	with	a	diameter	of	8	mm	were	 selected	
in	 the	 tumor	 and	 in	 the	background	 skin	of	 the	opposite	 side	of	
each	mouse,	and	the	fluorescence	intensities	were	calculated	using	
software	 as	 described	previously.23	 All	 animal	 experiments	were	
carried	out	according	to	the	Guidelines	for	Animal	Experiments	at	
Tokushima	University.
2.5 | Treatment with fluorouracil for xenograft 
tumors in nude mice
Sixteen	nude	mice	xenografted	with	LIM1215	cells	were	randomly	
assigned	 to	 treatment	with	 fluorouracil	 (5-FU)	or	a	control	group	
treated	with	vehicle	alone	(n	=	8	per	group).	When	the	tumor	size	
reached	 3-8	 mm	 in	 diameter,	 mice	 were	 injected	 with	 5-FU	 i.p.	
three	times	(once	a	week	for	3	weeks)	at	a	dose	of	150	mg/kg	or	
vehicle	 alone	 according	 to	 the	 schedule	 described	 in	 Figure	 S1a.	
Tumor	size	was	measured	with	a	Vernier	caliper	to	measure	length	
and	width	just	before	giving	5-FU	and	just	before	fluorescent	im-
aging	at	3	weeks	after	the	start	of	dosing.	Tumor	volume	(V)	was	
calculated	by	the	modified	ellipsoidal	formula:	V	=	length	×	(width
)2	×	0.5.24,25	Before	giving	5-FU	and	at	3	weeks,	mice	received	an	
injection	of	AF647-EGFR-Ab	into	the	tail	vein	and	fluorescence	in-
tensity	was	analyzed	48	hours	after	injection	using	IVIS	Spectrum.	
Fluorescence	intensity	of	each	tumor	was	calculated	as	described	
above.
2.6 | Veterinary endoscope for AOM‐treated rats
Azoxymethane	 (AOM;	 Sigma-Aldrich	Co.,	 St	 Louis,	MO,	USA)	was	
given	to	10	5-week-old	male	F344	rats	(Charles	River	Laboratories	
Japan,	Inc.,	Yokohama,	Japan)	s.c.	at	a	dose	of	15	mg/kg	once	a	week	
for	3	weeks	 according	 to	 the	 schedule	described	 in	Figure	S1b.	A	
Thin	Endoscope	for	Small	Animal	and	Laboratory	Animals	(TESALA)	
system	(AVS	Co.,	Ltd.,	Tokyo,	Japan)	was	used	to	observe	colorec-
tal	 mucosa	 under	 white	 light.	 For	 fluorescence	 observation,	 the	
TESALA	system	equipped	with	a	blue	(excitation)	filter	which	trans-
mits	410-500	nm	rays	for	excitation	of	the	probe	(WRATTEN	Gelatin	
Filter	No.47,	blue;	Eastman	Kodak	Co.,	Rochester,	NY,	USA)	and	a	
yellow	 (barrier)	 filter	which	 transmits	510-nm	 rays	 for	emission	of	
the	probe	(WRATTEN	Gelatin	Filter	No.12,	yellow;	Eastman	Kodak	
Co.)	was	used.
At	26	weeks,	rats	were	fasted	for	24	hours	and	given	an	enema	
with	 2	 mL	 PBS	 twice	 prior	 to	 colonoscopy	 for	 removal	 of	 feces.	
During	 the	procedure,	 rats	were	 anesthetized	with	2%	 isoflurane.	
A	 thin	 endoscope	with	 a	 diameter	 of	 2.7	mm	 (70	mm	 length,	AE-
E27110;	AVS	Co.	Ltd)	was	introduced	through	the	anus	and	inserted	
into	 the	 splenic	 flexure	 with	 gentle	 insufflation	 using	 a	 specially	
designed	cannula	(AE-E27110-CAN-S;	AVS	Co.	Ltd)	attached	to	an	
air-pumping	unit.	The	scope	was	then	slowly	withdrawn	and	the	col-
orectal	mucosa	was	 carefully	 observed	 under	white	 light.	 A	 3-mL	
enema	with	 AF488-EGFR-Ab	 (20	 μg/mL),	 which	was	 sufficient	 to	
immerse	the	distal	side	of	the	colorectum,	was	given	after	pretreat-
ment	with	or	without	non-labeled	mouse	anti-human	EGFR	mono-
clonal	 antibody	 (200	 μg/mL,	 sc-120;	 Santa	 Cruz	 Biotechnology).	
After	3	minutes,	2	mL	PBS	was	given	as	an	enema	twice	for	washing,	
and	fluorescence	observation	was	carried	out.	All	images	were	cap-
tured	in	a	dark	room.	Both	white	light	and	fluorescence	images	were	
recorded	on	a	hard	disk	video	recorder.	S/N	ratio	was	calculated	as	
described	previously.23
2.7 | Immunohistochemistry
Immunohistochemical	 staining	 for	 CEA	was	 carried	 out	 using	 the	
catalyzed	 signal	 amplification	 (CSA)	 system,	 as	 previously	 de-
scribed.26	A	rabbit	antihuman	CEA	monoclonal	antibody	(ab133633;	
Abcam,	Cambridge,	UK)	was	used	as	the	primary	antibody.	For	EGFR	
staining,	 the	 labeled	streptavidin-biotin-peroxidase	 (LSAB)	method	
was	carried	out	as	previously	described.27	A	rabbit	antihuman	EGFR	
monoclonal	antibody	(ab52894;	Abcam,	Cambridge,	UK)	was	used	as	
the	primary	antibody.
2.8 | Quantification of CEA‐positivity rate in 
tumor tissues
Carcinoembryonic	 antigen	 expression	 areas	were	 quantified	 using	
WinROOF	 Version	 6.3	 software	 (Mitani	 Corp.,	 Tokyo,	 Japan)	 as	
previously	described.28	Briefly,	sections	were	observed	and	photo-
graphed	using	an	Olympus	BX50	microscope	system	(Olympus	Corp.,	
Tokyo,	Japan).	Five	randomly	selected	fields	of	view	(4.3	×	3.2	mm)	
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were	captured	at	100×	magnification,	and	the	CEA	expression	area	
that	stained	brown	was	extracted	automatically	using	two	distinct	
macroinstructions	composed	chiefly	of	algorithms	for	color	extrac-
tion	based	on	 red-green-blue	 (RGB)	and	hue-luminosity-saturation	
(HLS)	 parameters.	 CEA-positive	 rate	 was	 determined	 by	 dividing	
the	area	stained	with	diaminobenzidine	(DAB)	by	the	entire	area	se-
lected,	and	the	average	rate	of	the	five	fields	was	calculated.
3  | RESULTS
3.1 | Cellular imaging and fluorescence intensity
We	first	attempted	 to	 image	 five	CRC	cell	 lines	with	various	ex-
pression	 levels	 of	 EGFR	 using	AF488-EGFR-Ab,	 and	 determined	
the	 fluorescence	 intensity	of	each	cell	 line.	A	strong	 fluorescent	
signal	 was	 observed	 along	 with	 the	 cell	 membrane	 of	 M7609	
and	 LIM1215	 cells,	whereas	 a	medium-intensity	 fluorescent	 sig-
nal	was	observed	 in	HT-29	cells	 (Figure	1A).	 In	 contrast,	 a	weak	
fluorescent	 signal	 and	almost	no	 signal	were	observed	 in	DLD-1	
and	 COLO320DM	 cells,	 respectively.	 Almost	 no	 signal	 was	 ob-
served	 in	M7609	cells	 treated	with	AF488-labeled	mouse	 IgG2a	
as	 a	 negative	 control.	 The	 respective	 fluorescence	 intensities	
(mean	 ±	 SD	 AU/cell)	 were	 65.0	 ±	 5.6	 in	 M7609,	 60.7	 ±	 5.5	 in	
LIM1215,	50.0	±	3.6	in	HT-29,	41.0	±	2.7	in	DLD-1,	and	29.3	±	3.2	
in	COLO320DM	cells.	EGFR	expression	profile	of	each	cell	line	was	
analyzed	by	flow	cytometry	(Figure	S2).	Mean	number	of	EGFR	(/
cell)	was	calculated	to	be	46	100	 in	M7609,	37	900	 in	LIM1215,	
25	000	in	HT-29,	12	800	in	DLD-1,	and	20	in	COLO320DM	cells,	
respectively.	There	was	a	significant	correlation	between	fluores-
cence	 intensity	 and	 the	 number	 of	 EGFR	 (Figure	 1B,	P < .01 by 
Pearson's	correlation	test).
3.2 | In vivo molecular imaging of LIM1215 and 
COLO320DM xenograft tumors in nude mice
Based	on	the	results	of	cellular	 imaging,	 in	vivo	molecular	 imaging	
was	 carried	out	using	 three	mice	xenografted	with	 a	 cell	 line	 that	
highly	 expresses	EGFR	 (LIM1215)	 and	 a	 low-EGFR	expression	 cell	
line	(COLO320DM).	Representative	images	from	each	mouse	group	
obtained	chronologically	are	shown	 in	Figure	2A.	No	fluorescence	
was	 observed	 in	 the	 tumor	 of	 each	 mouse	 before	 giving	 AF647-
EGFR-Ab.	A	clear	fluorescence	signal	 (5.0	×	108	AU)	was	observed	
in	 the	LIM1215	cell	 tumor	at	24	hours.	The	fluorescence	 intensity	
reached	a	maximum	(5.6	×	108	AU)	at	48	hours,	and	then	gradually	
decreased	until	96	hours.	In	contrast,	in	the	COLO320DM	cell	tumor,	
almost	 no	 fluorescence	 signal	 was	 observed	 at	 any	 time.	 When	
AF647-labeled	mouse	IgG2a	was	given	to	mice	as	negative	control,	
no	significant	signals	were	observed	at	any	timepoint.	The	remain-
ing	 two	 mice	 with	 LIM1215	 and	 COLO320DM	 cell	 tumors	 given	
with	AF647-EGFR-Ab	 showed	 similar	 imaging	 patterns.	 The	mean	
fluorescence	intensity	from	three	mice	at	each	timepoint	is	shown	in	
Figure	2B.	There	were	significant	differences	in	fluorescence	inten-
sities	between	the	LIM1215	and	COLO320DM	cell	tumor	groups	at	
all	timepoints	from	24	to	96	hours	(P	<	.01	by	Student's	t	test).
F I G U R E  1  Cellular	imaging	and	fluorescence	intensity	in	various	colorectal	cancer	(CRC)	cell	lines.	A,	Five	CRC	cell	lines	(M7609,	
LIM1215,	HT-29,	DLD-1,	COLO320DM)	were	incubated	with	Alexa	Fluor	488-labeled	mouse	antihuman	epidermal	growth	factor	receptor	
(EGFR)	monoclonal	antibody	(AF488-EGFR-Ab),	and	then	observed	by	confocal	laser	microscopy.	Alexa	Fluor	488-labeled	normal	mouse	
IgG2a	was	used	as	a	negative	control.	DAPI	was	used	for	nuclear	staining.	B,	Fluorescence	intensity	and	number	of	EGFR	in	each	cell	line	
were	determined	as	described	in	Materials	and	Methods2.	Correlation	between	fluorescence	intensity	and	number	of	EGFR	was	assessed	by	
Pearson's	correlation	test
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3.3 | In vivo molecular imaging of LIM1215 
xenograft tumors treated with 5‐FU
We	next	evaluated	 fluorescence	 images	of	LIM1215	xenograft	 tu-
mors	in	five	nude	mice	treated	with	5-FU	and	compared	them	with	
those	of	five	mice	treated	with	vehicle	alone,	according	to	the	treat-
ment	 schedule	 described	 in	 Figure	 S1a.	 Figure	 3A	 shows	 repre-
sentative	 images	of	 the	 tumors	 in	mice	 treated	with	vehicle	alone	
or	5-FU	at	48	hours	after	giving	AF647-EGFR-Ab.	A	clear	fluorescent	
signal	was	detected	 in	 the	site	of	 the	 tumor	of	 the	control	mouse	
(5.4	×	108	AU),	whereas	a	weaker	 fluorescent	signal	was	detected	
in	 the	site	of	 the	 tumor	of	 the	 treated	mouse	 (3.8	×	108	AU).	The	
remaining	four	mice	treated	with	5-FU	or	vehicle	alone	showed	simi-
lar	patterns.	The	mean	 fluorescence	 intensity	 (±	SD)	of	 the	 tumor	
in	each	mouse	over	time	was	plotted	after	giving	AF647-EGFR-Ab	
(Figure	3B).	Fluorescence	intensity	abruptly	 increased	at	24	hours,	
reaching	 a	 maximum	 at	 48	 hours,	 and	 then	 gradually	 decreased	
until	120	hours	in	both	the	treatment	group	and	the	control	group.	
However,	the	mean	fluorescence	intensities	in	the	treatment	group	
were	significantly	lower	than	those	in	the	control	group	at	all	time-
points	 from	24	 to	 120	 hours	 (P	 <	 .01	 by	 Student's	 t	 test).	 Similar	
results	were	 obtained	 using	 another	 CRC	 cell	 line	 PMF-ko14	 as	 a	
xenograft	tumor	(Figure	S3).	These	data	clearly	indicate	that	treat-
ment	with	anticancer	drugs	reduced	the	number	of	EGFR-expressing	
tumor	cells.
To	 investigate	 whether	 our	 EGFR	 imaging	 method	 is	 able	 to	
precisely	evaluate	the	therapeutic	efficacy	of	anticancer	drugs,	we	
quantified	 fluorescence	 intensity	 and	 determined	 its	 correlation	
with	viable	cell	volume	in	LIM1215	xenograft	tumors	in	mice	before	
and	after	treatment	with	5-FU.	Figure	4A	shows	changes	in	tumor	
volumes	measured	using	Vernier	calipers	before	and	3	weeks	after	
the	start	of	treatment.	Despite	giving	5-FU,	the	volumes	of	six	tu-
mors	 increased	 after	 treatment	 as	 compared	with	 the	 volume	be-
fore	treatment,	whereas	the	volume	of	two	tumors	showed	almost	
F I G U R E  2  Chronological	changes	of	
in	vivo	molecular	imaging	of	LIM1215	
and	COLO320DM	xenograft	tumors	in	
nude	mice.	A,	Nude	mice	xenografted	
with	LIM1215	or	COLO320DM	cells	were	
injected	with	AF647-epidermal	growth	
factor	receptor	(EGFR)-Ab	into	the	tail	
vein,	and	tumors	were	observed	using	
an	IVIS	Spectrum	system	(Perkin	Elmer,	
Waltham,	MA,	USA).	Alexa	Fluor	647-
labeled	normal	mouse	IgG2a	was	used	as	
a	negative	control.	B,	Mean	fluorescence	
intensity	of	the	tumors	from	three	mice	
(±	SD)	at	each	timepoint	is	shown
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no	 change	 after	 treatment.	 However,	 the	 fluorescence	 intensities	
in	all	eight	 tumors	decreased	after	 treatment	 (Figure	4B).	To	eval-
uate	 cell	 viability	 in	 tumors	 histologically,	 we	 excised	 the	 tumors	
and	carried	out	H&E	staining.	Representative	H&E	staining	patterns	
in	 tumors	after	 treatment	with	5-FU	and	vehicle	 alone	are	 shown	
in	Figure	4C,D.	H&E	staining	of	 tumors	treated	with	vehicle	alone	
showed	compacted	viable	tumor	cells	without	a	fibrotic	and	necrotic	
pattern	(Figure	4C).	In	contrast,	H&E	staining	in	5-FU-treated	tumor	
tissue	showed	extensive	fibrosis	and	necrosis	(Figure	4D).
In	order	to	quantify	the	viable	cells	in	tumor	tissues,	we	carried	
out	 immunohistochemical	 staining	 for	 CEA,	which	 is	 reportedly	 a	
good	marker	of	CRC	cells	with	high	sensitivity	and	specificity.29,30 
Representative	CEA	staining	patterns	in	tumors	after	treatment	with	
vehicle	alone	or	5-FU	are	shown	in	Figure	4E,F.	Immunostaining	of	
tumors	treated	with	vehicle	alone	for	CEA	showed	that	most	of	the	
cells	were	positive	 for	CEA	 (Figure	4E).	 In	 contrast,	 immunostain-
ing	 for	CEA	 in	5-FU-treated	 tumor	 tissue	showed	a	 reduced	num-
ber	 of	 positive	 cells	 resulting	 in	 a	 dappled	 distribution	 of	 signals	
(Figure	4F).	 The	mean	CEA-positivity	 rate	 in	 5-FU-treated	 tumors	
was	 31.4	 ±	 11.1%,	which	was	 significantly	 lower	 than	 that	 in	 the	
control	group	treated	with	vehicle	alone	 (72.6	±	3.0%,	Figure	4G).	
Moreover,	there	was	a	significant	correlation	between	the	percent-
age	decrease	in	fluorescence	intensity	and	the	CEA-positivity	rate	in	
each	tumor	(Figure	4H,	P	<	.01	by	Pearson's	correlation	test).	These	
data	suggest	that	fluorescence	intensity	reflects	the	viable	cell	vol-
ume	of	the	tumor	after	treatment	with	anticancer	drugs.	Thus,	our	
imaging	method	is	suitable	for	evaluation	of	the	therapeutic	efficacy	
of	anticancer	drugs.
3.4 | Molecular imaging of colorectal tumors by 
endoscopy in AOM‐treated rats
In	vivo	molecular	imaging	of	colorectal	tumors	in	AOM-treated	rats	
was	 carried	out	using	 a	 veterinary	 endoscope.	Representative	 im-
ages	of	a	tumor	under	white	light	and	EGFR	fluorescent	imaging	(rats	
#1,	#3)	are	shown	in	Figure	5A-D.	A	flat	isochromatic	tumor	was	ob-
served	 in	 the	colorectum	under	white	 light.	When	the	 fluorescent	
probe	was	administered	by	enema	 into	 the	colorectum	 (rectum	to	
splenic	flexure)	followed	by	washing	with	PBS,	a	strong	green	fluo-
rescence	signal	was	observed	at	the	same	site	in	the	rectum.	Mean	
S/N	 ratio	 calculated	 from	 fluorescent	 intensities	 of	 all	 polyps	was	
10.6	±	0.7	 (Figure	S4).	When	 the	colorectum	was	pretreated	with	
non-labeled	anti-EGFR	antibody,	the	fluorescent	signal	was	signifi-
cantly	suppressed	(Figure	5C,D),	suggesting	specificity	of	EGFR-tar-
geted	 imaging	with	 anti-EGFR-Ab.	 The	 S/N	 ratio	 also	 significantly	
decreased	(1.6	±	0.4,	P	<	.01	by	Student's	t	test;	Figure	S4).
Observation	of	the	colorectal	mucosa	removed	from	the	mouse	
showed	a	polyp	that	was	visible	to	the	naked	eye	 (Figure	5E).	The	
tumor	was	diagnosed	as	adenoma	based	on	histological	staining	with	
H&E	staining	(Figure	5F).	EGFR	immunohistochemistry	of	the	lesion	
showed	a	clear	expression	of	EGFR	in	the	tumor	cells	(Figure	5G)	de-
spite	a	faint	non-specific	signal	with	rabbit	IgG	as	a	negative	control	
(Figure	5H).
We	observed	colorectums	of	10	 rats	using	white	 light	and	 flu-
orescence	 imaging	with	AF488-EGFR-Ab.	White	 light	 observation	
showed	 one	 polyp	 in	 each	 colorectum	 of	 six	 rats,	 and	 no	 polyps	
in	 the	colorectum	of	 the	 remaining	 four	 rats.	Average	diameter	of	
the	polyps	observed	was	2.17	±	0.37	mm.	Molecular	 imaging	with	
AF488-EGFR-Ab	detected	all	 these	polyps	 in	the	same	 location	as	
that	observed	with	white	 light,	although	no	additional	new	polyps	
were	detected	(Table	1).	These	results	suggest	that	EGFR	molecular	
imaging	using	our	veterinary	fluorescent	endoscopic	system	may	be	
able	to	detect	a	small	polyp	with	a	diameter	of	approximately	2	mm.
4  | DISCUSSION
In	the	present	study,	we	clearly	visualized	CRC	cells	using	non-inva-
sive	optical	molecular	imaging	with	a	fluorescence-conjugated	anti-
EGFR	 antibody	 in	 vitro	 and	 in	 vivo	 in	 correlation	with	 the	 degree	
of	EGFR	expression.	Moreover,	we	showed	that	EGFR	fluorescence	
intensity	accurately	reflected	the	viable	cell	volume	in	tumors	after	
F I G U R E  3   In	vivo	molecular	imaging	of	LIM1215	xenograft	
tumor	treated	with	fluorouracil	(5-FU).	A,	Mice	were	i.p.	treated	
three	times	with	5-FU	or	vehicle	alone	as	described	in	Figure	S1a,	
and	then	injected	with	AF647-epidermal	growth	factor	receptor	
(EGFR)-Ab,	after	which	fluorescence	imaging	was	done	using	
an	IVIS	Spectrum	system	(Perkin	Elmer,	Waltham,	MA,	USA).	
Representative	images	of	tumors	in	mice	treated	with	vehicle	alone	
or	5-FU	48	h	after	giving	AF647-EGFR-Ab	are	shown.	B,	Mean	
fluorescence	intensity	(±	SD)	of	the	tumors	observed	in	five	mice	at	
each	timepoint	is	shown.	*P	<	.01	by	Student's	t	test
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treatment	with	5-FU.	This	is	essentially	the	first	study	to	show	the	
possibility	 that	molecular	 imaging	of	EGFR	 is	useful	 for	evaluating	
the	effect	of	chemotherapy.	Although	we	evaluated	the	therapeutic	
efficacy	of	5-FU	using	a	xenograft	model	rather	than	an	orthotropic	
colorectal	tumor	model,	our	results	may	suggest	that	EGFR	molecu-
lar	imaging	is	useful	for	evaluation	of	CRC	primary	lesions	using	fluo-
rescence	endoscopy.	Furthermore,	we	were	able	to	detect	a	benign	
small	adenoma	in	the	rat	colorectum	using	anti-EGFR	fluorescence	
imaging.	This	molecular	 imaging	method	may	 lead	 to	 the	develop-
ment	of	a	new	endoscopic	detection	method	with	less	oversight	for	
the	detection	of	small	benign	tumors	as	well	as	for	malignant	tumors.
Previous	 studies	 have	 used	 molecular	 imaging	 for	 ad-
enoma	 and	 adenocarcinoma	 using	 various	 fluorescent	
probes	 such	 as	 protease-activatable	 fluorescent	 probe,31 
γ-glutamyltranspeptidase-activatable	 probe,32	 and	 fluorescent-
labeled	 AKPGYLS	 peptide	 multimer.33	 Because	 anti-EGFR	 anti-
bodies	 such	 as	 cetuximab	 and	 panitumumab	 are	 currently	 used	
worldwide	 in	 clinical	 practice	 for	 the	 treatment	 of	 CRC,34,35	 it	
would	 be	 relatively	 easy	 to	 apply	 fluorescent-labeled	 anti-EGFR	
antibody	 for	 the	 diagnosis	 of	 human	 tumors.	 Moreover,	 when	
AF-EGFR-Ab	was	given	i.v.	in	mice,	it	showed	specific	and	strong	
binding	to	EGFR	in	the	xenograft	tumor	model	continuously	for	up	
to	approximately	96	hours	after	dosage,	indicating	advantages	for	
future	clinical	application.	However,	because	AF-EGFR-Ab	used	in	
the	xenograft	experiments	showed	very	little	reactivity	to	mouse	
EGFR	(Figure	S5),	further	experiments	including	fluorescent	inten-
sity	in	tumor	and	background	(S/N	ratio)	with	a	syngeneic	mouse	
model	are	required.
F I G U R E  4  Relationship	between	
epidermal	growth	factor	receptor	
(EGFR)	fluorescence	intensity	and	tumor	
viability	with	or	without	fluorouracil	
(5-FU)	treatment.	A,	Tumor	volumes	
of	xenografts	in	each	mouse	(n	=	8)	
before	and	after	5-FU	treatment	were	
plotted.	B,	Fluorescence	intensity	of	
the	xenograft	tumor	before	and	after	
5-FU	treatment	in	each	mouse	was	
plotted.	C-F,	Representative	H&E	and	
carcinoembryonic	antigen	(CEA)	staining	
patterns	in	the	tumor	after	vehicle	alone	
or	5-FU	treatment.	H&E	staining	after	
vehicle	treatment	(C),	or	5-FU	treatment	
(D),	immunohistochemical	staining	for	
CEA	after	vehicle	treatment	(E),	or	5-FU	
treatment	(F)	is	shown.	G,	CEA-positive	
rates	in	the	tumor	after	vehicle	treatment	
and	5-FU	treatment	were	plotted.	
*P	<	.01	by	Student's	t	test.	H,	Correlation	
between	the	percentage	decrease	of	
the	CEA-positive	rate	and	percentage	
decrease	of	fluorescence	intensity	in	
each	tumor	was	assessed	by	Pearson's	
correlation	test
(A) (B)
(C) (D)
(E)
(G) (H)
(F)
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Currently,	 clinical	 evaluation	 of	 the	 therapeutic	 effect	 of	 anti-
cancer	agents	on	solid	cancers	 is	done	using	RECIST	guidelines.6,7 
RECIST	 assessment	 is	 carried	 out	 by	 measuring	 the	 diameter	 of	
each	tumor	before	and	after	treatment	using	CT	images.	However,	
often	 the	 tumor	 size	 in	 a	CT	 image	 does	 not	 reflect	 viable	 tumor	
cell	volume.	 In	this	respect,	 the	method	to	detect	only	viable	cells	
in	the	tumor	is	superior	to	the	RECIST	method	with	CT	images	for	
evaluating	therapeutic	efficacy.	For	example,	positron-emission	to-
mography	(PET)	imaging	with	fluorodeoxyglucose	(FDG)	probes	has	
become	a	valuable	method	for	clinicians	because	 it	 reflects	 tumor	
viability	of	primary	CRC	and/or	metastatic	tumors.	Recently,	Turker	
and	associates	 synthesized	a	novel	PET	 imaging	probe	conjugated	
with	a	Fab′	fragment	of	an	anti-EGFR	antibody	and	showed	that	 it	
detected	colitis-associated	cancer	in	mice	with	a	high	target-to-back-
ground	ratio.36	However,	given	the	longer	survival	period	of	CRC	pa-
tients	as	a	result	of	the	use	of	molecular-targeting	agents,	 it	 is	not	
practical	to	repeatedly	use	this	radioactive	modality	in	patients.37,38 
Optical	molecular	imaging	technologies,	such	as	the	one	used	in	the	
present	 study,	 are	 less	harmful	 and	easier	 to	use	 than	procedures	
F I G U R E  5  Endoscopic	and	histological	
findings	of	colorectal	polyps	from	
azoxymethane	(AOM)-treated	rats.	A,B,	
Representative	endoscopic	image	of	a	
colorectal	polyp	in	an	AOM-injected	
rat	(rats	#1,	#3)	observed	using	a	thin	
endoscope.	C,D,	A	3-mL	aliquot	of	AF488-
epidermal	growth	factor	receptor	(EGFR)-
Ab	(20	μg/mL)	was	given	by	enema	with	
or	without	pretreatment	with	non-labeled	
EGFR-Ab	(200	μg/mL),	and	colorectal	
polyps	were	detected	by	fluorescent	thin	
endoscopy.	E,	The	entire	colorectum	was	
removed	from	the	rat.	Yellow	arrows	show	
a	small	polyp.	F,	Histopathological	findings	
of	the	resected	tumor	(H&E).	G,	EGFR	
immunohistochemical	staining	of	the	
polyp.	H,	Treatment	with	normal	rabbit	
IgG	as	a	negative	control
(A)
(C) (D)
(E)
(F) (G) (H)
(B)
TA B L E  1  Colorectal	polyps	detected	by	white	light	and	EGFR	
molecular	imaging	using	an	animal	endoscope	in	an	AOM-treated	
rat	model
Rat no.
White light 
image (n)
EGFR molecular 
image (n) Size (mm)
1 1 1 3
2 0 0 0
3 1 1 2
4 1 1 2
5 0 0 0
6 1 1 2
7 0 0 0
8 1 1 2
9 0 0 0
10 1 1 2
Total 6 6  
AOM,	azoxymethane;	EGFR,	epidermal	growth	factor	receptor.
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involving	 radioactive	agents.	Here,	we	 showed	 that	our	EGFR-tar-
geted	imaging	reflected	viable	tumor	cells.	This	was	also	consistent	
with	our	ex	vivo	data	of	xenograft	tumors	in	terms	of	distribution	of	
AF-EGFR-Ab;	when	frozen	sections	of	tumor	were	observed	at	low	
magnification	under	fluorescent	microscopy,	strong	fluorescent	sig-
nals	were	detected	throughout	the	tumor	from	mice	treated	with	ve-
hicle	alone,	whereas	reduced	levels	of	fluorescence	were	detected	in	
tumors	from	mice	treated	with	5-FU	that	gave	a	dappled	distribution	
of	signals	(Figure	S6).	However,	the	relationship	between	fluorescent	
intensity	 and	viable	 tumor	 cell	 volume	 should	be	 investigated	 fur-
ther.	In	addition,	our	EGFR-targeted	imaging	to	evaluate	the	effects	
of	 cancer	 therapy	 assumes	 that	 EGFR	expression	 is	 not	 downreg-
ulated	or	 upregulated	by	 the	 chemotherapy	 itself.	 To	 address	 this	
point,	we	 investigated	 relative	mRNA	 levels	 and	 EGFR	 number	 in	
CRC	cells	before	and	after	5-FU	treatment,	and	confirmed	that	there	
are	no	significant	changes	before	and	after	5-FU	treatment	(Figure	
S7).	Thus,	EGFR-targeted	imaging	is	a	potentially	useful	tool	for	eval-
uating	therapeutic	efficacy.
In	 the	present	 study,	we	were	able	 to	detect	 all	 six	 small	 ade-
nomas	that	were	2-3	mm	in	diameter.	To	date,	no	studies	have	re-
ported	 the	detection	of	colorectal	adenomas	using	EGFR-targeted	
molecular	imaging.	Thus,	EGFR-targeted	molecular	imaging	may	lead	
to	the	development	of	a	sensitive	detection	method	for	adenoma.	
However,	this	study	was	limited	to	cell	lines	and	animal	experiments	
and,	 therefore,	 further	 investigation	 for	 clinical	 application	will	 be	
needed.
For	clinical	 administration	with	 fluorescent	probes,	 two	 routes	
can	 be	 used	 to	 give	 AF-EGFR-Ab:	 local	 administration	 by	 direct	
spraying	 and	 i.v.	 administration.	 In	 the	 present	 study,	 we	 gave	
AF-EGFR-Ab	 by	 enema	 and	 obtained	 a	 relatively	 high	 S/N	 ratio	
(10.6	±	0.7).	When	AF-EGFR-Ab	was	given	i.v.	to	mice	in	preliminary	
experiments,	the	tumor	was	also	visualized	with	the	fluorescent	sig-
nal	although	the	S/N	ratio	was	relatively	low	(4.0	±	0.6;	Figure	S8).	
Further	experiments	with	more	animals	are	required	to	compare	the	
two	administration	routes.
Image	brightness	of	the	veterinary	endoscope	used	in	this	study	
was	 low	as	a	 result	of	 its	 thinness	 (Figure	5A),	 and	 the	brightness	
of	our	fluorescence	endoscopy	system	with	the	blue	and	yellow	fil-
ters	was	much	lower	(Figure	5B).	Brightness	of	the	thin	endoscope	
and	the	fluorescence	endoscope	with	the	two	filters	was	calculated	
to	be	23.7	and	4.8	 lumens,	 respectively,	based	on	the	 illumination	
intensities	(data	not	shown).	However,	the	image	brightness	of	en-
doscopes	for	use	in	humans	is	now	up	to	approximately	800	lumens	
(unpublished	data,	Olympus	Corp.,	2017).	The	brightness	of	the	aut-
ofluorescence	endoscope	(AFI;	Olympus	Corp.)	is	approximately	half	
that	value,	which	is	approximately	100-fold	higher	as	compared	with	
the	 veterinary	 fluorescent	 endoscope	 used	 in	 the	 present	 study.	
Therefore,	when	fluorescence	molecular	imaging	of	EGFR	is	applied	
to	 future	 human	 colonoscopy,	 it	 will	 be	 possible	 to	 obtain	 much	
brighter	and	clearer	images	for	detection	of	colorectal	tumors.
In	 conclusion,	 the	 results	 of	 our	 animal	 experiments	 suggest	
that	EGFR-targeted	molecular	imaging	may	be	useful	for	evaluating	
chemotherapeutic	efficacy,	as	indicated	by	viable	cell	volume,	more	
accurately	than	tumor	size.	This	EGFR	imaging	method	may	also	be	
useful	in	detecting	colorectal	adenoma	in	the	colorectum	for	colo-
noscopy.	This	 imaging	method	may	 lead	 to	advancements	 in	early	
detection	 and	 improved	diagnosis	 of	 colorectal	 tumors,	 as	well	 as	
therapeutic	evaluation	of	CRC.
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